Dapsone Impurity 17 | CAS 90309-26-5 - Request Quote
Dapsone Impurity 17
| SZ CAT No: | SZ-D044021 |
| CAS No | 90309-26-5 |
| Mol.F. | C12H10ClNO2S |
| Mol.Wt. |
267.7 |
| Inv. Status |
Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Hazard Statement:
Usage Note:
Dapsone Impurity 17 is chemically 4-[(3-Chlorophenyl)sulfonyl] benzenamine. Dapsone Impurity 17 is supplied with detailed characterization data compliant with regulatory guideline. Dapsone Impurity 17 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Dapsone.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 90309-26-5
Purchase 90309-26-5
Order 90309-26-5
Enquire 90309-26-5
price of 90309-26-5
90309-26-5 Supplier
90309-26-5 Manufacturer
90309-26-5 Exporter
buy high quality Dapsone Impurity 17
Purchase Dapsone Impurity 17
Dapsone Impurity 17 suppliers
Dapsone Impurity 17 manufacturers
Dapsone Impurity 17 price
Order Dapsone Impurity 17
Enquire Dapsone Impurity 17
Dapsone Impurity 17 cost
Dapsone Impurity 17 Supplier
Dapsone Impurity 17 Distributor
Dapsone Impurity 17 for Method Validation
Dapsone Reference Standard
Dapsone Impurity 17 for ANDA Filing
Dapsone Impurity 17 for Forced Degradation Studies
Dapsone Impurity 17 Identification Standards
Dapsone Impurity 17 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.


